MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of…
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the…
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results…
PacBio to leverage Chris’ extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB),…
New sequencing approach resolves the genetic complexity of a rare Mendelian condition MENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leader in high-quality, long-read sequencing,…
MENLO PARK, Calif., Jan. 23, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the Global Institute for Food Security (GIFS)…
MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading provider of highly accurate long-read sequencing solutions, announced a significant publication from Radboud University Medical Center…
Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK,…
MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discovery,…
Berry Genomics will leverage PacBio Vega System to develop long-read sequencing-based solutions for patients in China and other countries MENLO PARK, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ:…
MENLO PARK, Calif., Jan. 02, 2025 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at the…
MENLO PARK, Calif., Nov. 08, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be participating in the…
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Revenue of $40.0 million…
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negotiated…
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory Translations: Japanese | Chinese | Korean MENLO PARK, Calif., Nov. 06, 2024 (GLOBE…
If you have a question, need to check the status of an order, or are interested in purchasing an instrument, we're here to help.